You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Classical Hodgkin Lymphoma (cHL)

Showing 1 - 25 of 6,036
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Allogeneic Hematopoietic Cell Transplantation For Classical

Active, not recruiting
  • Lymphoma
  • Non-Interventional
  • Princeton, New Jersey
  • +1 more
Mar 14, 2022

Advanced Classical Hodgkin's Lymphoma in Brazil Treated With

Not yet recruiting
  • Hodgkin Lymphoma
  • No Intervention
  • Salvador, Bahia, Brazil
  • +5 more
Oct 23, 2023

Hodgkin Lymphoma Trial (pembrolizumab)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • (no location specified)
May 30, 2022

Hodgkin Lymphoma Trial in Moscow (Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Moscow, Russian Federation
    The Federal Budget-Funded Institution National Medical Surgical
Oct 31, 2022

Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma Trial in Guangzhou (PD-1 inhibitor, PD-1

Recruiting
  • Classical Hodgkin Lymphoma
  • Refractory or Relapsed Classical Hodgkin Lymphoma
  • PD-1 inhibitor
  • PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

Classical Hodgkin Lymphoma Trial in Charlottesville (Pembrolizumab, Doxorubicin, Vinblastine)

Recruiting
  • Classical Hodgkin Lymphoma
  • Charlottesville, Virginia
    University of Virginia
Jul 27, 2022

Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent Trial in United States (Nivolumab, Autologous

Recruiting
  • Classical Hodgkin Lymphoma
  • +2 more
  • Duarte, California
  • +4 more
Jun 27, 2022

Classical Hodgkin Lymphoma Trial in Nanjing (Camrelizumab, Investigator's choice of Chemotherapy)

Recruiting
  • Classical Hodgkin Lymphoma
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Feb 4, 2021

Hodgkin Disease Lymphoma Trial in China (Penpulimab, Investigator's choice of Chemotherapy)

Recruiting
  • Hodgkin Disease Lymphoma
  • Guangzhou, Guangdong, China
  • +5 more
Feb 15, 2022

Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma Trial in Worldwide (AZD4573)

Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Relapsed/Refractory Classical Hodgkins Lymphoma
  • Duarte, California
  • +33 more
Jan 5, 2023

Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • GEN3017
  • (no location specified)
Aug 25, 2023

Classical Hodgkin Lymphoma Trial in Philadelphia (Itacitinib, Everolimus)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Nov 28, 2022

Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)

Terminated
  • Hodgkin's Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 22, 2022

Immune Checkpoint Inhibitors and Radiotherapy in

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Immune checkpoint inhibitor
  • Trieste, Italy
    SC Ematologia Ospedale Maggiore
Sep 14, 2020

Classical Hodgkin Lymphoma Trial in Cologne (Tislelizumab)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
Aug 5, 2022

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular

Recruiting
  • Ann Arbor Stage I Hodgkin Lymphoma
  • +13 more
  • Birmingham, Alabama
  • +16 more
Nov 23, 2021

Hodgkin Disease Trial in Worldwide (Nivolumab, Doxorubicin, Vinblastine)

Active, not recruiting
Has Results
  • Hodgkin Disease
  • Los Angeles, California
  • +37 more
Oct 25, 2021

Hodgkin Lymphoma Trial in Cologne (Pembrolizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
Sep 19, 2023

Classical Hodgkin Lymphoma Trial in Guangzhou (Zimberelimab 240mg)

Recruiting
  • Classical Hodgkin Lymphoma
  • Zimberelimab 240mg
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-Sen University Cancer Ce
Jun 15, 2023

Classical Hodgkin Lymphoma Trial in Worldwide (Tislelizumab)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Detroit, Michigan
  • +34 more
Dec 29, 2022

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Hodgkin Lymphoma Trial in Saint Petersburg (Prolgolimab, Combination with prolgolimab and bendamustine)

Recruiting
  • Hodgkin Lymphoma
  • Saint Petersburg, Russian Federation
  • +1 more
Mar 3, 2023

Classical Hodgkin Lymphoma Trial in Cologne (Nivolumab, Adriamycin, Vinblastine)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Cologne, Germany
    University Hospital of Cologne
Aug 5, 2022

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)

Not yet recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +13 more
  • (no location specified)
Feb 2, 2023